-
Uncategorized8 hours agoSTAT+: Novartis doubles down on molecular glue strategy
Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox. Medicare drug spending is climbing...
-
Uncategorized8 hours agoDaltonTx launches AI drug discovery platform
DaltonTx has launched an AI drug discovery platform which could help scientists “make better-informed decisions earlier in the discovery process”. The platform, called Dalton, seeks to integrate agentic AI,...
-
Uncategorized8 hours ago
Sky-high Parabilis, Kailera IPOs spur optimism—but only for derisked biotechs
Biotechs are benefitting from the AI tech frenzy and inflation, but validated pipelines and careful planning are still key to the recent record-setting IPOs, experts say.
-
Uncategorized9 hours ago
Takeda’s AI-designed pill bests BMS’ Sotyktu in head-to-head psoriasis trial
Takeda eyes an FDA run for its investigational psoriasis pill after the drug elicited total skin clearance in more than 35% of patients at 16 weeks—more...
-
Uncategorized9 hours agoSTAT+: Pharmalittle: We’re reading about employer coverage of obesity drugs, another Sanofi setback, and more
Top of the morning to you, and a fine one it is. Sunny skies and mild breezes are enveloping the Pharmalot campus once again, making it...
-
Uncategorized10 hours agoSTAT+: Enliven Therapeutics’ leukemia drug shows promise in new study
A targeted drug from Enliven Therapeutics induced molecular responses in nearly half of patients with advanced leukemia, including higher response rates in patients treated at an...
-
Uncategorized11 hours ago
SonoThera bags $125M series B to advance safer gene therapies
SonoThera bags $125M series B to advance safer gene therapies
-
Uncategorized11 hours ago
Novartis tightens bond with Orionis in up to $1.4B molecular glue deal
It’s the latest Big Pharma deal for molecular glue technology and Novartis’ second with Orionis Biosciences, after first linking up in March 2020. The backloaded agreement...
-
Uncategorized11 hours agoTakeda’s $4B TYK2 drug tops Bristol Myers’ Sotyktu in head-to-head test
The results support Takeda’s long-held belief in zasocitinib’s superiority and could help it gain a commercial advantage over Bristol’s therapy. Read More
-
Uncategorized14 hours agoOpinion: How long Covid’s scientific stalemate made it politically erasable
Mitchell Miglis had two months left. The Stanford University neurology professor had spent two years studying what long Covid does to the human nervous system —...
An obesity drug deep-dive, and peptides move mainstream
RFK Jr. claims his calendar is publicly available. We’ve been trying to get it for a year
